A5015648859- HIV/AIDS drug development and treatment
- HIV Research and Treatment
- HIV/AIDS Research and Interventions
- HIV-related health complications and treatments
- Hepatitis C virus research
- HIV, Drug Use, Sexual Risk
- Influenza Virus Research Studies
- Cytomegalovirus and herpesvirus research
- HIV/AIDS oral health manifestations
- Folate and B Vitamins Research
- Hepatitis B Virus Studies
- Respiratory viral infections research
- Lipoproteins and Cardiovascular Health
- Liver Disease Diagnosis and Treatment
- Animal Disease Management and Epidemiology
- Drug-Induced Adverse Reactions
- Diabetes Management and Education
- Sex work and related issues
- Adolescent Sexual and Reproductive Health
- Complement system in diseases
- Ethics in Clinical Research
- Autoimmune Bullous Skin Diseases
- T-cell and Retrovirus Studies
- Inflammatory Biomarkers in Disease Prognosis
- Mosquito-borne diseases and control
Bordeaux Population Health
2019
Inserm
2019
Université de Bordeaux
2019
Quest Clinical Research (United States)
2019
Complejo Hospitalario Universitario de Santiago
2019
Triangle
2016
Research Triangle Park Foundation
2004-2005
GlaxoSmithKline (United States)
2004
Medical College of Wisconsin
2003
Abstract Introduction Although weight gain has been reported with the use of integrase strand transfer inhibitors (InSTI), concurrent tenofovir alafenamide (TAF) implicated in recent studies. This study examined changes people living HIV (PLWH) who switched from disoproxil fumarate (TDF) to TAF, clarify relative contribution core agents versus TDF TAF switch. Methods Antiretroviral‐experienced, virologically suppressed PLWH U.S. OPERA cohort were included if they (5NOV2015‐28FEB2019) and...
Psychiatric symptoms (PSs) are reported to occur frequently in people living with HIV and may be associated specific antiretrovirals. We analyzed PSs observed dolutegravir (DTG) other prescribed anchor drugs.Selected (insomnia, anxiety, depression, suicidality) occurring HIV-positive patients during DTG treatment across 5 randomized clinical trials (3 double-blind), the Observational Pharmaco-Epidemiology Research & Analysis (OPERA) cohort, among cases spontaneously ViiV Healthcare were...
<h3>Background</h3>To estimate the clinical benefit of highly active antiretroviral therapy (HAART) initiation vs deferral in a given month patients with CD4 cell counts less than 800/μL.<h3>Methods</h3>In this observational cohort study human immunodeficiency virus type 1 seroconverters from CASCADE (Concerted Action on SeroConversion to AIDS and Death Europe), we constructed monthly sequential nested subcohorts between January 1996 May 2009, including all eligible HAART-naive, AIDS-free...
The first complete long-acting antiretroviral therapy (ART) regimen, cabotegravir + rilpivirine (CAB RPV LA) injectable, was approved in the US for HIV-1 treatment individuals on a stable regimen with viral load < 50 copies/mL, no failure history, and resistance to either or rilpivirine. We describe injection schedule adherence virologic effectiveness of CAB LA routine clinical care US. From OPERA® cohort, all adults HIV who received their ≥ 1 continuation injections between 21 January 2021...
The prevalence and predisposing factors of thrombotic microangiopathy (TMA) in the era highly active antiretroviral therapy (HAART) were evaluated among patients Collaborations Human Immunodeficiency Virus (HIV) Outcomes Research/US cohort. Of 6022 patients, 17 (0.3%) had TMA, with unadjusted incidences per 100 person-years 0.079 for 0.009 thrombocytopenic purpura, 0.069 hemolytic-uremic syndrome. Compared without TMA lower mean CD4(+) cell counts (197 vs. 439 cells/mm(3); P=.0009) higher...
HLA-B*57:01 screening was added to clinical care guidelines in 2008 reduce the risk of hypersensitivity reaction from abacavir. The uptake and incidence were assessed a prospective cohort United States evaluate effectiveness this intervention. We included all patients initiating an abacavir-containing regimen for first time pre-HLA-B*57:01 period (January 1, 1999 June 14, 2008) or post-HLA-B*57:01 (June 15, January 2016). Yearly both physician panel-adjudicated reactions calculated compared....
Highly active antiretroviral therapy (HAART) is recommended when the absolute CD4(+) T lymphocyte count <200 cells/mm(3), and it should be considered that > or =200, although optimal timing =200 unclear. Because preliminary data had suggested a low percentage (%CD4) associated with disease progression in persons initiating HAART who have higher CD4, we sought to further characterize predictive utility of %CD4.We conducted an observational study Collaborations HIV Outcomes Research/US cohort...
Increases in lipids have been observed people with HIV (PWH) switching from tenofovir disoproxil fumarate (TDF) to alafenamide (TAF). We assessed changes low-density lipoprotein cholesterol (LDL-C) and triglycerides (TG) following a switch TDF TAF.Adults ≥1 lipid measure before after TAF were identified the OPERA cohort. Multivariable linear regression using generalized estimating equations was used estimate predicted over time on TAF, modeled flexibly splines.A total of 6451 PWH switched...
Approximately 20% of newly diagnosed people with HIV (PWH) in the United States have advanced infection, yet literature on current antiretroviral therapy (ART) options is limited. The discontinuation/modification and effectiveness common regimens were compared among ART-naïve infection (CD4 cell count <200 cells/μL).ART-naïve adults initiating bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) or a boosted darunavir (bDRV)-, dolutegravir (DTG)-, elvitegravir/cobicistat (EVG/c)-based...
Multi-class resistance, intolerance, and drug-drug interactions can result in unique antiretroviral (ART) combinations for heavily treatment-experienced (HTE) people living with HIV (PLWH). We aimed to compare clinical outcomes between HTE non-HTE PLWH.Eligible ART-experienced PLWH care the OPERA® Cohort were identified a cross-sectional manner on December 31, 2016 observed from date of initiation ART regimen taken until loss follow up, death, study end (December 2018), or becoming (non-HTE...
Background. Highly active antiretroviral therapy (HAART) prolongs short-term survival in patients with HIV/AIDS. HAART has only been available since 1996; thus, no longterm data are available. Computer simulation models extrapolating can provide estimates of long-term survival. These may assist and clinicians treatment planning. The authors construct a computer model based on observational to estimate cohort HIV/AIDS undergoing HAART. Methods. use from the Collaboration HIV Outcomes...
Objective Although highly active antiretroviral therapy has been shown to lower plasma HIV-1 RNA in HIV infection, many patients do not reach the target goal of undetectable viremia. We evaluated whether risk clinical progression varies by level viral suppression achieved. Design Patients Collaborations Outcomes Research/United States cohort who maintained stable levels either <400, 400 20,000, or >20,000 copies/mL during a run-in period at least 6 months were studied. Baseline was first day...
Abstract Background Hepatitis C (HCV) screening rates remain low despite recommendations of one-time for asymptomatic adults and annual people at higher risk HCV acquisition. We sought to determine if alerts in CHORUS™, a clinical decision support system (CDSS), could improve the diagnosis ratio. Methods A machine learning-based model calculated percent chance returning positive test individuals eligible selected OPERA® clinics. Alerts providing score factors contributing were disseminated...
Abstract Background People with HIV (PWH) develop more chronic illnesses at younger ages. Frequent healthcare interactions can help early detection and management of disease. We aimed to describe the frequency timing testing related disease among PWH receiving long-acting (LA) antiretroviral therapy (ART) versus oral ART in OPERA® cohort. Methods identified treatment-experienced, suppressed (viral load &lt; 50 copies/mL) adults initiating cabotegravir plus rilpivirine (CAB+RPV) LA...
Abstract Background Pre-exposure prophylaxis (PrEP) has been available since 2012, yet only 3 in 10 individuals at increased risk of human immunodeficiency virus (HIV) acquisition are currently prescribed PrEP the US. We assessed factors related to prescription by healthcare professionals (HCPs). Methods HCPs that use CHORUS phone application were invited a survey including 50 multiple-choice questions prescribing. Responses summarized. Results From 04OCT2023 22MAR2024, 156 completed (Table...
Abstract Background Cabotegravir long-acting (CAB LA) pre-exposure prophylaxis (PrEP) consists of 2 initiation injections given 1 month apart, followed by a continuation injection every months, with HIV testing before each injection. We compared characteristics CAB LA and oral PrEP users described patterns dosing testing. Methods All individuals ≥12 years old new or ≥1 from 21Dec2021-30Jun2023 in the OPERA cohort were included. was completed if first received ≤60 days apart. Patterns...
Abstract Background Cabotegravir + rilpivirine long-acting (CAB+RPV LA) injectable administered once a month or every two months is the first complete LA antiretroviral (ART) regimen approved for HIV-1 treatment. It indicated treatment experienced individuals with viral loads (VL) &lt; 50 copies/mL. CAB+RPV has attributes that may make it good option women, who represent ∼20% of people HIV in US and experience unique challenges reduce psychosocial concerns around adherence, stigma,...
Abstract Background Cabotegravir + rilpivirine (CAB+RPV) injections, the first complete long-acting (LA) antiretroviral therapy (ART) regimen, was approved by FDA in January 2021 for ART-experienced people with HIV (PWH) who are virologically suppressed (VL &lt; 50 copies/mL). Among individuals non-suppressed ≥ 30 copies/mL) at initiation, high rates of virologic suppression were observed demonstration project Ward 86 CAB+RPV LA. We LA real-world utilization and effectiveness over 2...
Abstract Objectives Our objective was to compare the immunological responses commonly used antiretroviral therapy (ART) regimens among people with advanced HIV in USA and assess virological outcomes regimen persistence. Methods This study included ART‐naïve adults infection (CD4 cell count <200 cells/μL) initiating ART bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF), boosted darunavir (bDRV), dolutegravir (DTG), or elvitegravir (EVG/c)‐containing between 1 January 2018 31...
Background: Double-dose raltegravir is recommended in HIV1infected patients with tuberculosis.A previous phase 2 study showed similar efficacy of standard 400 mg BID, 800 or efavirenz-based regimens.We aimed to assess noninferiority BID efavirenz HIV1-infected tuberculosis.Methods: ANRS 12300 Reflate TB2 an open-label, 3, randomized trial conducted Brazil, Côte d'Ivoire, France, Mozambique, and Vietnam.ART-na€ ıve aged ≥18 years on tuberculosis treatment for weeks were (1:1) receive 600 QD...
With obesity on the rise among people living with HIV (PLWH), there is growing concern that weight gain may result as an undesired effect of antiretroviral therapy (ART). This analysis sought to assess association between ART regimens and changes in body mass index (BMI) ART-experienced, virologically suppressed PLWH. PLWH ≥18 years age Observational Pharmacoepidemiology Research Analysis (OPERA) cohort were included for if prescribed a new regimen containing one following core agents:...
Objectives: To describe the prevalence and incidence of prediabetes type 2 diabetes mellitus (T2DM) among people living with HIV (PLHIV) evaluate association between antiretroviral therapy (ART) initiation dolutegravir (DTG), elvitegravir/cobicistat (EVG/c), raltegravir (RAL), or boosted darunavir (bDRV) incident T2DM. Design: Longitudinal study based on electronic health records 29 674 PLHIV from Observational Pharmaco-Epidemiology Research Analysis (OPERA) cohort. Methods: Calculate T2DM...
Summary: Plasma viral load from 71 HIV-1-infected neonates was measured by using Amp-RT, an ultrasensitive quantitative reverse transcriptase (RT) assay and nucleic acid sequence-based amplification (NASBA), RNA-based assay. Results were then compared with those obtained detection of proviral DNA in peripheral blood mononuclear cells (PBMCs) polymerase chain reaction (PCR) Turnbull analysis. At 5 days life, 50% positive 30% NASBA positive, 20% DNA-PCR positive. Through the first 12 Amp-RT...
Objectives To assess the risk of chronic kidney disease (CKD) associated with tenofovir disoproxil fumarate (TDF) use by baseline D:A:D CKD score. Methods Adult antiretroviral therapy (ART)‐naïve people living HIV (PLWH) initiating treatment, estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73 m 2 , were identified in OPERA cohort. was defined as two or more consecutive eGFR < > 90 days apart. Associations between TDF use, and incident assessed incidence rates (IRs; Poisson...